Antibody Characterization Service
With antibody characterization services, you can gain clear insight into the purity and performance of your antibody reagents. Our company offers a full range of antibody characterization services, which can help you make progress in the development of rare disease antibody therapies.
Overview of Antibody Characterization
Antibody characterization encompasses all aspects of antibody performance, including binding specificity, affinity, kinetics, stability, and interactions with antigens or other molecules. By thoroughly characterizing antibodies, we can gain valuable insights into their behavior that can provide the basis for applications such as diagnostics, therapeutics, and research tools.
Fig.1 SPR technique can be used to detect antibody affinity (Das, Sreyashi, et al. 2023)
Our Services
The antibody characterization services provided by our company can help you gain insight into the functional properties of antibodies, such as binding specificity, affinity, and avidity. This information helps in the selection of the most appropriate recombinant antibody development protocol for antibody therapy for rare diseases. Our services include but are not limited to:
- Antibody Sequencing
Our antibody sequencing service provides a one-stop solution from your hybridoma cell line to your antibody sequence, which can provide reliable data for optimizing therapeutic antibody development protocols.
Hybridoma cell line delivery
mRNA extraction and reverse transcription
DNA sequencing
Sub-cloning into a standard vector
PCR amplification and data analysis
- KD Measurement
KD (Dissociation Constant) is used to measure antibody affinity. It can help researchers assess the strength of antibody-antigen interactions, guide drug design and screening, and optimize therapeutic options.
| Project | Technology | Time |
|---|---|---|
| Antibody-antigen affinity assay | Surface plasmon resonance (SPR) | 2 weeks |
| Antibody-cell affinity assay | Surface plasmon resonance imaging (SPRi) | 2-3 weeks |
| Antibodies interact with other biological macromolecules | Interferometry | 2-3 weeks |
- Fc-mediated Effector Functional Assays
The efficacy of most antibody drugs results primarily from their ability to elicit cytotoxicity potencies via Fc-mediated functions. Our company has successfully developed a full range of well-established assays for precisely elaborating functional profiles of therapeutic antibodies including but not limited to:
- ADCC Assay
- FcγR Binding Assay
- Antibody ADCP Assay
- FcRn Binding Assay
- CDC Assay
- C1q Binding Assay
- Epitope Mapping
Antibody epitope mapping is the process of identifying and characterizing specific regions or sites on an antigen that are recognized and bound by antibodies. This information can be used to understand the molecular basis of antibody-antigen interactions. Our epitope mapping technologies include but are not limited to:
- Peptide scanning
- Site-specific mutagenesis
- X-ray crystallography
- Alanine scan
- Nuclear magnetic resonance spectroscopy (NMR)
- Hydrogen deuterium exchange mass spectrometry (HDX-MS)
- Stability Assessment
The stability of antibodies is critical to maintaining their potency, specificity, and binding affinity. Our company provides a series of stability evaluation experiments to ensure the quality and efficacy of antibodies, including but not limited to:
- Nano differential scanning fluorimetry (nanoDSF)
- Hydrophobic interaction chromatography (HIC)
- Dynamic light scattering (DLS)
- Size exclusion chromatography with multi-angle light scattering (SEC-MALS)
Our company has the capabilities and resources to provide professional communication and problem-solving support to ensure that we can quickly respond to the changing needs of your rare disease therapy research projects. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Das, Sreyashi, et al. "Surface plasmon resonance (SPR) sensor for cancer biomarker detection." Biosensors 13.3 (2023): 396.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.